Glutamate receptors as therapeutic targets for Parkinson's disease
KA Johnson, PJ Conn… - CNS & Neurological …, 2009 - ingentaconnect.com
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms
including tremor and bradykinesia. The primary pathophysiology underlying PD is the …
including tremor and bradykinesia. The primary pathophysiology underlying PD is the …
Metabotropic glutamate receptors in the basal ganglia motor circuit
PJ Conn, G Battaglia, MJ Marino… - Nature Reviews …, 2005 - nature.com
In recent years there have been tremendous advances in our understanding of the circuitry
of the basal ganglia and our ability to predict the behavioural effects of specific cellular …
of the basal ganglia and our ability to predict the behavioural effects of specific cellular …
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
D Rylander, H Iderberg, Q Li, A Dekundy, J Zhang… - Neurobiology of …, 2010 - Elsevier
L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor
fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been …
fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been …
Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease
K Fuxe, D Marcellino, S Genedani… - … : official journal of the …, 2007 - Wiley Online Library
Future therapies in Parkinson's disease may substantially build on the existence of intra‐
membrane receptor–receptor interactions in DA receptor containing heteromeric receptor …
membrane receptor–receptor interactions in DA receptor containing heteromeric receptor …
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
I Sebastianutto, MA Cenci - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•Targeting specific mGluRs normalizes excessive glutamate/GABA transmission in
PD and LID models.•mGluR5 NAMs normalise biochemical and molecular changes …
PD and LID models.•mGluR5 NAMs normalise biochemical and molecular changes …
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys
GJ Masilamoni, JW Bogenpohl, D Alagille, K Delevich… - Brain, 2011 - academic.oup.com
Degeneration of the dopaminergic nigrostriatal system and of noradrenergic neurons in the
locus coeruleus are important pathological features of Parkinson's disease. There is an …
locus coeruleus are important pathological features of Parkinson's disease. There is an …
Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease
S Duty - CNS drugs, 2012 - Springer
The appearance of levodopa-induced dyskinesia (LID) and ongoing degeneration of
nigrostriatal dopaminergic neurons are two key features of Parkinson's disease (PD) that …
nigrostriatal dopaminergic neurons are two key features of Parkinson's disease (PD) that …
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
A Dekundy, M Pietraszek, D Schaefer, MA Cenci… - Brain research …, 2006 - Elsevier
The present study was devoted to investigate the effects of the metabotropic glutamate
receptor (mGluR) 5 antagonist [(2-methyl-1, 3-thiazol-4-yl) ethynyl] pyridine (MTEP) and the …
receptor (mGluR) 5 antagonist [(2-methyl-1, 3-thiazol-4-yl) ethynyl] pyridine (MTEP) and the …
On the role of P2X7 receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X7 receptor antagonist A-438079
D Marcellino, D Suárez-Boomgaard… - Journal of neural …, 2010 - Springer
The role of the ATP-gated receptor, P2X 7, has been evaluated in the unilateral 6-OHDA rat
model of Parkinson's disease using the P2X 7 competitive antagonist A-438079. Nigral P2X …
model of Parkinson's disease using the P2X 7 competitive antagonist A-438079. Nigral P2X …
Intramembrane receptor–receptor interactions: a novel principle in molecular medicine
K Fuxe, M Canals, M Torvinen, D Marcellino… - Journal of neural …, 2007 - Springer
In 1980/81 Agnati and Fuxe introduced the concept of intramembrane receptor–receptor
interactions and presented the first experimental observations for their existence in crude …
interactions and presented the first experimental observations for their existence in crude …